Low Dose Naltrexone (LDN) may be the most effective drug available today at preventing the disability caused by Multiple Sclerosis, yet most doctors do not know about LDN because it has not been approved by the FDA for Multiple Sclerosis.
Unfortunately, because generic Naltrexone has been without patent protection for many years, no pharmaceutical company will bear the expense of the clinical trials necessary for FDA approval of LDN’s new special uses. It is now up to public institutions to seize the opportunity that LDN offers.
For more information visit: www.LDNaware.org